Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Sotirios Georgopoulos & Vasilios Papastergiou. (2021) An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opinion on Pharmacotherapy 22:6, pages 729-741.
Read now
Read now
David Y. Graham, Maria Pina Dore & Hong Lu. (2018) Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Review of Anti-infective Therapy 16:9, pages 679-687.
Read now
Read now
Articles from other publishers (36)
Diego Burgos-Santamaría, Olga P Nyssen, Antonio Gasbarrini, Dino Vaira, Ángeles Pérez-Aisa, Luís Rodrigo, Rinaldo Pellicano, Alma Keco-Huerga, Manuel Pabón-Carrasco, Manuel Castro-Fernandez, Doron Boltin, Jesus Barrio, Perminder Phull, Juozas Kupcinskas, Laimas Jonaitis, Inmaculada Ortiz-Polo, Bojan Tepes, Alfredo J Lucendo, José María Huguet, Miguel Areia, Natasa Brglez Jurecic, Maja Denkovski, Luís Bujanda, June Ramos-San Román, Antonio Cuadrado-Lavín, Judith Gomez-Camarero, Manuel Alfonso Jiménez Moreno, Angel Lanas, Samuel Jesús Martinez-Dominguez, Enrique Alfaro, Ricardo Marcos-Pinto, Vladimir Milivojevic, Theodore Rokkas, Marcis Leja, Sinead Smith, Ante Tonkić, György Miklós Buzás, Michael Doulberis, Marino Venerito, Frode Lerang, Dmitry S Bordin, Vincent Lamy, Lisette G Capelle, Wojciech Marlicz, Daniela Dobru, Oleksiy Gridnyev, Ignasi Puig, Francis Mégraud, Colm O'Morain & Javier P Gisbert. (2023)
Empirical rescue treatment of
Helicobacter pylori
infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on
H. pylori
management (Hp-EuReg)
. Gut 72:6, pages 1054-1072.
Crossref
Crossref
Pezhman Alavinejad, Morteza Nayebi, Abazar Parsi, Eman Abdelsameea, Mohammed Hussien Ahmed, Ahmad Hormati, Dao Viet Hang, Mehdi Pezeshgi Modarres, Bahman Cheraghian, Siamak Baghaee, Tahmine Farbod Ara, Quang Trung Tran, Nitin Shanker Behl, Seyed Jalal Hashemi, Mohammed Alboraie, Saif Salman, Le Nha, Árpád V. Patai, Eskandar Hajiani & Ali Akbar Abravesh. (2023)
Levofloxacin+Tetracycline Quadruple Regimen for Eradication of
Helicobacter pylori
: A Multicenter Multinational Randomized Controlled Trial
. Middle East Journal of Digestive Diseases 15:1, pages 12-18.
Crossref
Crossref
Chih-An Shih, Chang-Bih Shie, Wei-Chen Tai, Seng-Kee Chuah, Hsi-Chang Lee & Ping-I Hsu. (2023)
Update on the second-line treatment of
Helicobacter pylori
infection: a narrative review
. Therapeutic Advances in Gastroenterology 16.
Crossref
Crossref
Zhongxue Han, Yueyue Li, Qingzhou Kong, Jing Liu, Juan Wang, Meng Wan, Minjuan Lin, Boshen Lin, Wenlin Zhang, Yuming Ding, Shaotong Wang, Yijun Mu, Miao Duan, Xiuli Zuo & Yan‐qing Li. (2022)
Efficacy of bismuth for antibiotic‐resistant
Helicobacter pylori
strains eradication: A systematic review and meta‐analysis
. Helicobacter 27:6.
Crossref
Crossref
Jiunn‐Wei Wang, Ping‐I Hsu, Ming‐Hong Lin, John Kao, Feng‐Woei Tsay, I‐Ting Wu, Chang‐Bih Shie & Deng‐Chyang Wu. (2022)
The efficacy of culture‐guided
versus
empirical therapy with high‐dose proton pump inhibitor as third‐line treatment of
Helicobacter pylori
infection: A real‐world clinical experience
. Journal of Gastroenterology and Hepatology 37:10, pages 1928-1934.
Crossref
Crossref
Olga P. Nyssen, Dino Vaira, Ángeles Pérez Aísa, Luis Rodrigo, Manuel Castro-Fernandez, Laimas Jonaitis, Bojan Tepes, Liudmila Vologzhanina, María Caldas, Angel Lanas, Alfredo J. Lucendo, Luis Bujanda, Juan Ortuño, Jesús Barrio, Jose M. Huguet, Irina Voynovan, Jorge Perez Lasala, Aiman Silkanovna Sarsenbaeva, Luis Fernandez-Salazar, Javier Molina-Infante, Natasa Brglez Jurecic, Miguel Areia, Antonio Gasbarrini, Juozas Kupčinskas, Dmitry Bordin, Ricardo Marcos-Pinto, Frode Lerang, Marcis Leja, Gyorgy M. Buzas, Yaron Niv, Theodore Rokkas, Perminder Phull, Sinead Smith, Oleg Shvets, Marino Venerito, Vladimir Milivojevic, Ilkay Simsek, Vincent Lamy, Peter Bytzer, Lyudmila Boyanova, Lumír Kunovský, Christoph Beglinger, Michael Doulberis, Wojciech Marlicz, Adrian Goldis, Ante Tonkić, Lisette Capelle, Ignasi Puig, Francis Megraud, Colm O’ Morain, Javier P. Gisbert, Giulia Fiorinni, Ilaria Maria Saracino, Manuel Pabon Carrasco, Alma Keco Huerga, Enrique Alfaro Almajano, Samuel Jesus Martinez Dominguez, Horacio Alonso Galan, Benito Velayos, Carmen Dueñas Sadornil, Jose Maria Botargues Bote, Pedro Luis Gonzalez-Cordero, Miguel Areia, Blas Jose Gomez Rodriguez, Rinaldo Pellicano, Óscar Nuñez, Francesco Franceschi, Sergey Alekseenko, Monica Perona, Rustam Abdulkhakov, Manuel Dominguez-Cajal, Pedro Almela Notari, Judith Gomez Camarero, Manuel Jimenez Moreno, Alicia Algaba, Fernando Bermejo, Jose Maria Botargues Bote, Javier Tejedor Tejada, Elida Oblitas Susanibar, Doron Boltin, Sotirios Georgopoulos, Colm OMorain, Asghar Qasim, Ian Beales, Natalia Bakulina, Galina Fadeenko, Peter Malfertheiner, Rosa Rosania, Tatiana Ilchishina, Pavel Bogomolov, Igor Bakulin, Oleg Zaytsev, Antonietta Gerarda Gravina, Marco Romano, Alfredo Di Leo, Giuseppe Losurdo, Ludmila Grigorieva, Pedro Delgado Guillena, Marinko Marusic, Dragan Jurcic, Natalia Nikolaevna Dekhnich, Eduardo Iyo, Luisa Carmen de la Peña Negro, Natalia Baryshnikova, Natalia Bakanova, Halis Simsek, Cem Simsek, Oleksiy Gridnyev, Miguel Fernandez-Bermejo, Teresa Angueira, Rafael Ruiz-Zorrilla Lopez, Barbara Gomez, Mila Kovacheva-Slavova, Adi Lahat, Javier Alcedo, Ana Campillo, Liya Nikolaevna Belousova, Ramon Pajares Villarroya, Neven Ljubicic, Marko Nikolic, Jesús M. González-Santiago, Diego Burgos Santamaría, Anna Pakhomova, Izabela Sekulic-Spasic, Matteo Ghisa, Fabio Farinati, Sabir Irfan Sagdati, Nikola Panic, Frederic Heluwaert, Edurne Amorena, Leticia Moreira, Gloria Fernandez Esparrach, Ekaterina Yuryevna Plotnikova, Michal Kukla, Victor Kamburov, Luis Javier Lamuela Calvo, Ivan Rankovic, Antonio Cuadrado Lavín, Yolanda Arguedas Lazaro, Victor Gonzalez Carrera Agnieszka Dobrowolska, Piotr Eder & Alla Kononova. (2022) Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology 20:10, pages 2243-2257.
Crossref
Crossref
Peter Malfertheiner, Francis Megraud, Theodore Rokkas, Javier P Gisbert, Jyh-Ming Liou, Christian Schulz, Antonio Gasbarrini, Richard H Hunt, Marcis Leja, Colm O'Morain, Massimo Rugge, Sebastian Suerbaum, Herbert Tilg, Kentaro Sugano & Emad M El-Omar. (2022)
Management of
Helicobacter pylori
infection: the Maastricht VI/Florence consensus report
. Gut 71:9, pages 1724-1762.
Crossref
Crossref
Javier P. Gisbert, Javier Alcedo, Javier Amador, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Luis Fernández-Salazar, Emili Gené, Ángel Lanas, Alfredo J. Lucendo, Javier Molina-Infante, Olga P. Nyssen, A. Pérez-Aisa & Ignasi Puig. (2022) V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterología y Hepatología 45:5, pages 392-417.
Crossref
Crossref
Javier P. Gisbert, Javier Alcedo, Javier Amador, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Luis Fernández-Salazar, Emili Gené, Ángel Lanas, Alfredo Lucendo, Javier Molina-Infante, Olga P. Nyssen, A. Pérez-Aisa & Ignasi Puig. (2022) V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 45:5, pages 392-417.
Crossref
Crossref
Hong Li, Yalin Shen, Xiaona Song, Xiaoqiong Tang, Renwei Hu, Barry James Marshall, Hong Tang & Mohammed Benghezal. (2022)
Need for standardization and harmonization of
Helicobacter pylori
antimicrobial susceptibility testing
. Helicobacter 27:2.
Crossref
Crossref
Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim & Miyoung Choi. (2021) Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. The Korean Journal of Internal Medicine 36:4, pages 807-838.
Crossref
Crossref
Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim & Miyoung Choi. (2021) Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. The Korean Journal of Medicine 96:3, pages 160-189.
Crossref
Crossref
Alfred Nelson, Yan Bi & Dana Harris. (2021)
Helicobacter Pylori
: a comprehensive review for primary care providers
. Romanian Journal of Internal Medicine 59:2, pages 112-118.
Crossref
Crossref
Yeon‐Ji Kim, Woo Chul Chung & Dae Bum Kim. (2021)
Efficacy of bismuth added to standard triple therapy as the first‐line eradication regimen for
Helicobacter pylori
infection
. Helicobacter 26:3.
Crossref
Crossref
Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim & Miyoung Choi. (2021) Evidence-Based Guidelines for the Treatment of <i>Helicobacter pylori</i> Infection in Korea 2020. Gut and Liver 15:2, pages 168-195.
Crossref
Crossref
Hyo-Joon Yang, Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim & Miyoung Choi. (2021) Salvage Regimens after Failure of Previous Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 21:1, pages 59-71.
Crossref
Crossref
Hye-Kyung Jung, Seung Joo Kang, Yong Chan Lee, Hyo-Joon Yang, Seon-Young Park, Cheol Min Shin, Sung Eun Kim, Hyun Chul Lim, Jie-Hyun Kim, Su Youn Nam, Woon Geon Shin, Jae Myung Park, Il Ju Choi, Jae Gyu Kim & Miyoung Choi. (2020) Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 20:4, pages 261-287.
Crossref
Crossref
Javier P. Gisbert. (2020) Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 25:21, pages 5084.
Crossref
Crossref
Tiankuo Yang, Renwei Hu, Xiaoqiong Tang, Yalin Shen, Alfred Tay, Xuenan Pi, Gang Wang, Aleksandra W Debowski, Keith A Stubbs, Mohammed Benghezal, Barry J Marshall, Hong Li & Hong Tang. (2020)
Susceptibility-guided bismuth quadruple therapies for resistant
Helicobacter pylori
infections
. Precision Clinical Medicine 3:2, pages 127-135.
Crossref
Crossref
Hideki Mori & Hidekazu Suzuki. (2020)
Update on quinolone-containing rescue therapies for
Helicobacter pylori
infection
. World Journal of Gastroenterology 26:15, pages 1733-1744.
Crossref
Crossref
Sung Eun KimJi Hun RohMoo In Park, Seun Ja ParkWon MoonJae Hyun KimKyoungwon JungJae Joon Heo. (2019)
Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
Helicobacter pylori
Eradication Therapy
. The Korean Journal of Gastroenterology 73:1, pages 26.
Crossref
Crossref
Yee Hui Yeo, Chia‐Chen Hsu, Chiao‐Chin Lee, Hsiu J Ho, Jaw‐Town Lin, Ming‐Shiang Wu, Jyh‐Ming Liou & Chun‐Ying Wu. (2018)
Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line
Helicobacter pylori
eradication
. Journal of Gastroenterology and Hepatology 34:1, pages 59-67.
Crossref
Crossref
Alessia Savoldi, Elena Carrara, David Y. Graham, Michela Conti & Evelina Tacconelli. (2018) Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 155:5, pages 1372-1382.e17.
Crossref
Crossref
Te-Fu Lin & Ping-I Hsu. (2018)
Second-line rescue treatment of
Helicobacter pylori
infection: Where are we now?
. World Journal of Gastroenterology 24:40, pages 4548-4553.
Crossref
Crossref
Eskandar Hajiani, Pezhman Alavinejad, Nahid Avandi, Abdol Rahim Masjedizadeh & Ali Akbar Shayesteh. (2018) Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East Journal of Digestive Diseases 10:4, pages 242-248.
Crossref
Crossref
Amin Talebi Bezmin Abadi & Yoshio Yamaoka. (2018) Helicobacter pylori therapy and clinical perspective. Journal of Global Antimicrobial Resistance 14, pages 111-117.
Crossref
Crossref
Huo-Ye Gan, Tie-Li Peng, You-Ming Huang, Kai-Hua Su, Lin-Li Zhao, Li-Ya Yao & Rong-Jiao Yang. (2018) Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial. Scientific Reports 8:1.
Crossref
Crossref
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Ignasi Puig, Sheila López-Góngora, David Suarez & Xavier Calvet. (2018)
Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for
Helicobacter pylori
. Helicobacter 23:3, pages e12488.
Crossref
Crossref
Ping-I Hsu, Feng-Woei Tsai, Sung-Shuo Kao, Wen-Hung Hsu, Jin-Shiung Cheng, Nan-Jing Peng, Kuo-Wang Tsai, Huang-Ming Hu, Yao-Kuang Wang, Seng-Kee Chuah, Angela Chen & Deng-Chyang Wu. (2017) Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. American Journal of Gastroenterology 112:9, pages 1374-1381.
Crossref
Crossref
D N Andreev, D T Dicheva & I V Maev. (2017) Possibilities for optimization of eradication therapy for Helicobacter pylori infection in modern clinical practice. Terapevticheskii arkhiv 89:2, pages 84-90.
Crossref
Crossref
William D Chey, Grigorios I Leontiadis, Colin W Howden & Steven F Moss. (2017) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology 112:2, pages 212-239.
Crossref
Crossref
Qi Chen, Wei Zhang, Qingyan Fu, Xiao Liang, Wenzhong Liu, Shudong Xiao & Hong Lu. (2016) Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. American Journal of Gastroenterology 111:12, pages 1736-1742.
Crossref
Crossref
Anthony O'Connor, Wolfgang Fischbach, Javier P. Gisbert & Colm O'Morain. (2016)
Treatment of
Helicobacter pylori
infection 2016
. Helicobacter 21:S1, pages 55-61.
Crossref
Crossref
Elizabeth A. Marcus, George Sachs & David R. Scott. (2016) Eradication of Helicobacter pylori Infection. Current Gastroenterology Reports 18:7.
Crossref
Crossref
Maria Pina Dore, Hong Lu & David Y Graham. (2016)
Role of bismuth in improving
Helicobacter pylori
eradication with triple therapy
. Gut 65:5, pages 870-878.
Crossref
Crossref
David Y. Graham. (2016)
Hp-normogram (normo-graham) for Assessing the Outcome of
H. pylori
Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype
. Helicobacter 21:2, pages 85-90.
Crossref
Crossref